Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S has announced the execution of a substantial share repurchase program, with the company buying back B shares for up to DKK 2.1 billion between February and April 2024, as part of a larger DKK 20 billion buyback plan over 12 months. Since the program’s start, Novo Nordisk has repurchased 1,550,500 B shares at an average price of DKK 863.73 each, reflecting the company’s strong commitment to shareholder value. This move aligns with Novo Nordisk’s continued efforts to drive change in the treatment of serious chronic diseases and enhance access to its medications globally.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
